文献速递免疫规划

婴儿联合接种PHiD-CV与4CMenB疫苗的免疫原性分析

Immunogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administered concomitantly with the meningococcal serogroup B (4CMenB) vaccine in infants: A post-hoc analysis in a phase 3b, randomised, controlled trial.
PubMed 文献 · Vaccine · 2019-07-18

该事后分析基于一项3b期随机对照试验,评估婴儿同时接种PHiD-CV与4CMenB疫苗的免疫原性。婴儿随机分组接受4CMenB+MenC-CRM或仅MenC-CRM,两组均按巴西免疫规划接种PHiD-CV。结果显示两组抗肺炎球菌抗体应答范围相似,提示4CMenB联合接种似乎不影响PHiD-CV的抗体应答。

要点

  • 婴儿联合接种4CMenB与PHiD-CV后,抗肺炎球菌抗体应答与单独接种组相似。
  • 4CMenB联合接种似乎不影响PHiD-CV的免疫原性。
  • 该结论来自3b期随机对照试验的事后分析,需谨慎解读。

核心结论

  • 4CMenB联合接种似乎不影响婴儿对PHiD-CV的抗体应答。

研究设计与样本

  • 3b期随机对照试验的事后分析(NCT01339923),婴儿随机分为4CMenB+MenC-CRM组或MenC-CRM组。
  • 两组均按巴西国家免疫规划接种PHiD-CV(3+1程序:3、5、7、12月龄)。
  • 在疫苗接种前、第2剂后1个月、加强前及加强后1个月评估抗体应答。

主要发现

  • 两组抗肺炎球菌抗体应答处于相似范围。

临床怎么用

  • 临床联合接种4CMenB与PHiD-CV时,无需担心对肺炎球菌疫苗免疫应答的明显干扰。

局限性

  • 事后分析,证据等级低于预设主要分析。
  • 原文未报告具体样本量、抗体几何平均浓度及置信区间等详细数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No data are currently available on immunogenicity of higher-valent pneumococcal conjugate vaccines when co-administered with a 4-component meningococcal serogroup B vaccine (4CMenB). METHODS: Post-hoc analysis of pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) immunogenicity when co-administered with 4CMenB (2 + 1 schedule) and/or a CRM-conjugated meningococcal serogroup C vaccine (MenC-CRM) in a trial assessing 4CMenB reduced schedules and co-administration with MenC-CRM (NCT01339923). Infants were randomized to receive 4CMenB and MenC-CRM (Group 1) or MenC-CRM (Group 2) at 3, 5, and 12 months (M) of age. Both groups received PHiD-CV (3 + 1 schedule) as part of the Brazilian national immunisation programme at 3 M, 5 M, 7 M, and 12 M of age. Antibody responses were assessed pre-vaccination, 1 M post-dose 2, pre-booster, and 1 M post-booster. RESULTS: Anti-pneumococcal antibody responses were in similar ranges in the two study groups. CONCLUSIONS: 4CMenB co-administration did not seem to impact antibody responses to PHiD-CV in infants.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Safadi MAP, Martinon-Torres F, Weckx LY, et al. Immunogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administered concomitantly with the meningococcal serogroup B (4CMenB) vaccine in infants: A post-hoc analysis in a phase 3b, randomised, controlled trial. Vaccine. 2019. PMID: 31327652. doi:10.1016/j.vaccine.2019.07.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。